^
Association details:
| Biomarker: | PTEN deletion + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ocifisertib (CFI-400945) (PLK4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P3-07-14 A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237
Published date:
11/22/2022
Excerpt:
CFI-400945 is a selective oral inhibitor of Polo-like Kinase 4 (PLK4)...49 patients were enrolled across 3 cohorts: 1: triple negative; 2: ER+/HER2- PTEN low (by IHC); 3: ER+/HER2-, PTEN intact….The PTEN loss group has been slow to accrue and remains open. Responses in the ER+/HER2- arm are encouraging – results from patients remaining on study are awaited and correlative studies to identify features associated with responses are underway.
Trial ID:
